Mt. Arlington and Princeton Clinical Research Firms Form Alliance
Exodon LLC and Primera Analytical Solutions Corp., New Jersey-based clinical research firms headquartered in Mt. Arlington and Princeton, respectively, have entered into a non-exclusive strategic alliance agreement.
Exodon offers beginning-to-end early drug, biologic and nutraceutical development services from its clinical research units in the US, India, the Philippines, and Argentina. Exodon’s early drug and nutraceutical development includes multinational regulatory filings, PK/PD, BA/BE, and Phase I - IIb clinical trials. Late phase development include site selection and patient recruitment and study management for clinical trials at its SMO and TMO sites.
Primera specializes in providing bioanalytical, analytical, formulation and clinical trial analysis services for the pharmaceutical, biotechnology, agrochemical, cosmetic, and dietary supplement industries. Specific services includemethod feasibility, development, validation, method transfer, and sample analysis.
“This new business relationship will enable Exodon and Primera to jointly offer arange of services that would not be possible individually,” said Gerald Tramontano, Ph.D., Vice President, Clinical Research Operations at Exodon.
“Together, it will also allow us to offer better pricing options to our early pharmaceutical and nutraceutical clients given laboratory costs eat up a significant amount of the study budget for these types of trials,” added Paul Ernest de Leon, Director of Business Development for Exodon’s Product R&D department.
For example, this will allow Exodon to conduct such study requirements as method development, chemical validation and stability tests, and will provide Primera with applicable clinic-related assistance and facility for its research studies.
Exodon's mission is to transform research participation into an everyday connection for patients, doctors, and clients.
Primera partners with its clients in a variety of ways. The company provides customized analysis for individual studies, functions as the virtual QC department forstability assessment and product release, and performs strategic consulting in clinical trial feasibility and design.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
